On 1 November, Boston Scientific closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of CR Bard.
The acquisition enables Boston Scientific to provide a broader portfolio of EP tools, including solutions for cardiac catheter ablations with advanced therapeutic catheters, diagnostic catheters, electrophysiology recording systems and intracardiac access devices.
“Completing this transaction is an important part of our global strategy to grow and transform our EP business,” said Pete Sommerness, general manager, Electrophysiology, Boston Scientific. “We believe that the complementary capabilities that this transaction brings, including expertise in capital equipment sales and service, will enable us to offer more complete solutions to help electrophysiologists diagnose and treat patients with cardiac arrhythmias.”
Boston Scientific also expects the additional capabilities brought by the acquisition, including extended reach in strategic global markets, will help accelerate launches of key EP technologies such as the recently approved IntellaTip MiFi XP ablation catheter and next-generation Rhythmia Mapping System.